Directorio

Es posible que algunos contenidos no estén disponibles en español.
402 clinical trials found.
Hematologic Malignancies and Cellular Therapy

We are doing this study to find out if an experimental drug called CAP-100 (study drug) is a safe and effective treatment for people who have CLL or SLL that is not responding to standard treatments. We also want to know what dose of this study drug works best.

Compensation: No
Oncology
Hematologic Malignancies and Cellular Therapy

We are doing this study to find out if an experimental therapy called CB-011 (the study drug) is a safe and effective option for people who have relapsed or refractory multiple myeloma.

Compensation: No
Oncology
Hematologic Malignancies and Cellular Therapy

We are doing this study to monitor the health and quality of life of people who participated in clinical trials for GM T cell therapies.

Compensation: No
Oncology
Hematologic Malignancies and Cellular Therapy

We are doing this study to find out if an experimental drug called iberdomide (the study drug) is a safe and effective option for multiple myeloma (MM). We also want to what the most appropriate dose and timing for taking the study drug should be.

Compensation: No
Oncology
Hematologic Malignancies and Cellular Therapy

We are doing this study to find out if an experimental drug called CC-92480 (the study drug) is a safe and effective treatment for multiple myeloma. We also want to figure out the most appropriate dose and schedule for giving the study drug to multiple myeloma patients.

Compensation: No
Oncology
Brain, Spinal Cord and Nerves

We are doing this study to find out if an experimental cell therapy called NRTX-1001 (the study drug) is a safe and effective treatment for drug-resistant mesial temporal lobe epilepsy (MTLE). We want to know if the study drug can reduce seizures in people who are not getting relief from conventional treatments.

Compensation: Yes
Ages: 18-65
Non-Oncology
Duke University Hospital
Genitourinary Cancer

We are doing this study to find out if an investigational drug called CG0070 (the study drug) is safe and effective for patients who have NMIBC that does not respond to BCG treatment.

Compensation: Yes
Ages: 18-90
Oncology
Duke University Hospital
Genitourinary Cancer

We are doing this study to learn if a combination of chemotherapies and immunotherapies (carboplatin, cabazitaxel, nivolumab and ipilimumab) slows cancer growth in patients with metastatic neuroendocrine or aggressive variant prostate cancer. We also want to learn about the types of side effects that patients have while they are taking these study drugs together.

Compensation: No
Ages: 18-110
Oncology
Duke University Hospital, Duke Raleigh Hospital